SEB Equities analyst Christopher Udhe downgraded Calliditas Therapeutics to Hold from Buy with a SEK 208 price target after Asahi Kasei announced an agreement to acquire Calliditas for about $39 per ADS or about $1.1B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALT:
- Wynn Resorts upgraded, PayPal initiated: Wall Street’s top analyst calls
- Calliditas Therapeutics downgraded to Neutral from Buy at Citi
- CHMP Endorses Calliditas’ Kinpeygo for IgAN
- Calliditas Therapeutics downgraded to Hold from Buy at Jefferies
- Calliditas Therapeutics downgraded to Neutral from Buy at H.C. Wainwright